Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/04—Ortho- or peri-condensed ring systems
  • C07D221/18—Ring systems of four or more rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention relates to compositions and a method for treating a patient having cancer. More specifically, the present invention is directed to novel indenoisoquinoline derivatives and to their use in cancer therapy.
• the control and cure of cancer represents one of our most challenging health problems.
• the treatment of cancer can be approached by several modes of therapy including surgery, radiation, chemotherapy or a combination of any of these treatments.
• Chemotherapy continues to be an indispensable therapy for inoperable or metastatic forms of the disease.
• the discovery of compounds specifically targeting cancer cells, or the cellular mechanisms involved in the proliferation of cancer cells can provide significant advancement in the eradication or control of cancer.
• the selection of compounds having effective anticancer activity is complicated by the still limited knowledge of cancer cell biology and biochemistry. Therefore, development of new effective anti-cancer agents remains heavily dependent on screening of new compounds for cytotoxic activity.
• Antineoplastic drug candidates exhibit enhanced cytotoxicity against cancer cells relative to normal cells.
• Methods of screening for anticancer activity have focused on several targets: (1) the ability of a compound to inhibit tumor growth and/or progression in animal studies; (2) inhibition of cell growth/proliferation in cell lines of cancerous origin; and (3) inhibition of intracellular processes necessary for the growth or propagation of cancer cells.
• the mouse L 1210 leukemia cell line was initially the preferred model system used for screening compounds for anti-cancer activity.
• the P388 murine leukemia system was found to be more sensitive and predictive than L1210
• the mouse L1210 leukemia cell line was initially the preferred model system used for screening compounds for anti-cancer activity.
• the P388 murine leukemia system was found to be more sensitive and predictive than L1210 leukemia system; it has been used as a primary screen during the past decade.
• the compounds of the present invention were screened for antineoplastic activity using the COMPARE screening methodology. The results demonstrate that the compounds are antineoplastic agents for use in treating human cancers.
• Anticancer agents are known to act through a variety of mechanisms to destroy or inhibit the proliferation of cancer cells. For example, some agents are antimetabolites which act as false substrates in the biochemical processes of cancer cells.
• One compound which has this mechanism of action is methotrexate, an analog of folic acid, which functions in part by binding to dihydrofolate reductase, thereby preventing the formation of guanine and adenine from the folic acid precursor molecule.
• methotrexate inhibits the ability of cancer cells to construct DNA by inhibiting the proper metabolism of folic acid.
• anticancer agents act by alkylating DNA strands, thereby producing defects in the normal double helical structure of the DNA molecule. This alkylation may cause the formation of breaks and inappropriate links between (or within) strands of DNA. Such disruption of the DNA structure, if not repaired by intracellular repair mechanisms, impairs the cell's ability to replicate it's DNA.
• alkylating anticancer agents are cyclophosphamide and chlorambucil.
• Some anticancer agents target the intracellular mechanisms involved in replication of the DNA strand itself. Replication of a cell's genetic material requires a means to pull the DNA double helix apart into two strands. This separation is typically accomplished by the enzyme topoisomerase I. Disruption of the function of this enzyme results in DNA strand breaks in cells that are dividing, thereby causing the death of the dividing cell. Because cancer cells grow and reproduce at a much faster rate than normal cells, they are more vulnerable to topoisomerase inhibition than are normal cells. Thus, agents that inhibit topoisomerase I are known to be potent anticancer agents.
• camptothecin was shown to be an inhibitor of topoisomerase I and a potent anticancer agent; unfortunately, camptothecin also produced toxic side effects.
• the search for potent inhibitors of topoisomerase I with lessened toxicity to normal cells continues.
• R is hydrogen, formyl, phenyl, phenyl substituted with C,-C 6 alkoxy or C,-C 6 alkyl, or R, is a group -(CH 2 ) m Z, wherein m is 1-6 and Z is selected from the group consisting of hydrogen, hydroxy, carboxy, formyl, C r C 6 alkyl, carbo-(C,-C 6 alkoxy), C 2 -C 6 alkenyl, phenyl, C C 6 alkylamino, and C)-C 6 hydroxyalkylamino;
• R 2 ' and R 4 are independently selected from the group consisting of hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl, C,-C 6 alkoxy, phenoxy and benzyloxy, or R 2 and R 2 ' taken together form a group of the formula -OCH 2 O-;
• the protons on the carbon atoms at fusion bond a are in a cis-configuration across bond a.
• the compound of Formula I has the following substituents: R ⁇ is -(CH 2 ) m 04 and m is 3-6; n is zero (0) and a is a double bond; and R 2 , R 2 ', R 3 , R 3 ' and R 4 are hydrogen.
• R ⁇ is -(CH 2 ) m 04 and m is 3-6; n is zero (0) and a is a double bond; and R 2 , R 2 ', R 3 , R 3 ' and R 4 are hydrogen.
• Formula I has the following substituents: R, is C 2 -C 4 alkyl or C 2 -C 4 alkenyl; R 2 and R ' are C,-C 4 alkoxy; R 3 and R 3 ' taken together form a group of the formula -OCH 2 O-; and R 4 is hydrogen.
• R is (CH 2 ) m OH and m is 3-6; n is zero (0) and a is a double bond; R 2 and R 2 ' are C,-C 3 alkoxy; R 3 and R 3 ' taken together form a group of the formula - OCH 2 O-; and R 4 is hydrogen.
• a further embodiment of the present invention includes the compound of Formula I wherein: R ⁇ is C r C 3 alkyl or C 2 -C 4 alkenyl; n is one (1) and a is a single bond; R 3 and R 3 ' taken together form a group of the formula - OCH 2 O-; and R 4 is hydrogen.
• Another embodiment of the present invention includes the compound of Formula I wherein: R, is -(CH 2 ) m COOH and m is 1-4; n is zero (0) and a is a double bond; and R 2 , R 2 ', R 3 , R 3 ' and R 4 are hydrogen.
• R is -(CH 2 ) m COOH and m is 1-4; n is zero (0) and a is a double bond; and R 2 , R 2 ', R 3 , R 3 ' and R 4 are hydrogen.
• Other compounds of the present invention are represented by the following formula:
• R is phenyl or phenyl substituted with C,-C 6 alkoxy or C r C 6 alkyl, or R, is a group -(CH 2 ) m Z wherein m is 1-6 and Z is selected from the group consisting of hydrogen, hydroxy, carboxy, formyl, C r C 6 alkyl, carbo-(C r C 6 alkoxy), C 2 -C 6 alkenyl, phenyl, C r C 6 alkylamino, and C r C 6 hydroxyalkylamino, provided that when Z is hydrogen, m is 2-6;
• R 2 , R 2 ' and R 4 are independently selected from the group consisting of hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl, C r C 6 alkoxy, phenoxy and benzyloxy, or R 2 and R 2 ' taken together form a group of the formula -OCH 2 O-;
• R 3 and R 3 ' are independently selected from the group consisting of hydrogen, C r C 6 alkyl, C,-C 6 alkoxy, C 2 -C 6 alkenyl, phenoxy, and benzyloxy, or R 3 and R 3 ' taken together form a group of the formula -OCH 2 O-; and wherein X is a pharmaceutically acceptable anion.
• a “pharmaceutically acceptable anion” is defined as any non-toxic mono-, di-, or trivalent anions. Exemplary of such are Br, CI “ , SO 4 "2 , PO “3 , acetate, CO 3 “2 and HCO " . It is understood that the stoichiometry of the salts of Formula II are dependent on the valence of the anion component and the ratio of cationic to anionic components is such as to provide a neutral salt.
• a compound of Formula II has the following substituent groups: R, is C ⁇ Q alkyl; R 2 and R 2 ' are C r C 3 alkoxy; R 3 and R 3 ' taken together form a group of the formula -OCH 2 -O-; and R 4 is hydrogen.
• the present invention further provides pharmaceutical formulations comprising an effective amount of an indenoisoquinoline compound of this invention for treating a patient having cancer.
• an effective amount of the indenoisoquinoline compound is defined as the amount of the compound which, upon administration to a patient, inhibits growth of cancer cells, kills malignant cells, reduces the volume or size of the tumors or eliminates the tumor entirely in the treated patient.
• the effective amount to be administered to a patient is typically based on body surface area, patient weight, and/or patient condition.
• body surface area may be approximately determined from patient height and weight (see e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, pages 537-538 (1970)).
• An effective amount of the indenoisoquinoline compounds of the present invention is defined as any amount useful for inhibiting the growth of (or killing) cancer cells in a patient.
• Such effective amounts range from about 5 mg/kg to about 500 mg/kg, more preferably from about 5 mg/kg to about 250 mg/kg, and most preferably about 5 to about 150 mg/kg.
• Effective doses will also vary, as recognized by those skilled in the art, dependent on route of administration, excipient usage and the possibility of co-usage with other therapeutic treatments including other anti-tumor agents, and radiation therapy.
• the pharmaceutical formulation may be administered via the parenteral route, including subcutaneously, intraperitoneally, intramuscularly and intravenously.
• parenteral dosage forms include aqueous solutions of the active agent, in isotonic saline, 5% glucose or other well-known pharmaceutically acceptable liquid carrier.
• the indenoisoquinoline compound is dissolved in a saline solution containing 5% dimethyl sulfoxide and 10% Cremphor EL (Sigma Chemical Company).
• Cremphor EL Cremphor EL
• Additional solubilizing agents such as cyclodextrins, which can form specific, more soluble complexes with the present indenoisoquinoline compounds, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the indenoisoquinoline compounds.
• the present compound can also be formulated into dosage forms for other routes of administration utilizing well-known methods.
• the pharmaceutical compositions can be formulated, for example, in dosage forms for oral administration in a capsule, a gel seal or a tablet.
• Capsules may comprise any well-known pharmaceutically acceptable material such as gelatin or cellulose derivatives.
• Tablets may be formulated in accordance with conventional procedure by compressing mixtures of the active indenoisoquinoline and solid carriers, and lubricants well- known to those familiar with the art. Examples of solid carriers include starch, sugar and bentonite.
• the compounds of the present invention can also be administered in a form of a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder and conventional fillers and tableting agents.
• a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder and conventional fillers and tableting agents.
• indenoisoquinoline 1 The synthesis of an indenoisoquinoline 1 has been previously reported. Compound 1 was subsequently found to be cytotoxic in human cancer cell cultures. More recently, a COMPARE analysis indicated that the cytotoxicity profile of 1 is similar to that of the topoisomerase I inhibitors camptothecin and saintopin. When tested for activity against topoisomerase, compound 1 was in fact found to induce DNA cleavage in the presence of topoisomerase I. However, the cleavage site specificity differed from that of camptothecin in that compound 1 did not cleave at all of the sites characteristic of camptothecin, while some DNA cleavage sites were unique to compound 1.
• compound 1 did not produce detectable DNA unwinding, suggesting that in contrast to other non-camptothecin topoisomerase inhibitors, it is not a DNA intercalator.
• the present invention describes the development of new topoisomerase I inhibitors and potential anticancer agents which have been developed based upon the activities associated with compound 1.
• indenoisoquinolines 3-8 lacking the methylenedioxy and methoxy substituents of 1 were synthesized by reacting commercially available benz[d]indeno[l,2-6]pyran-5,l 1-dione (2) with various primary amines (Schemel). The reactions were carried out at room temperature in chloroform and the yields were generally high.
• OCH OCH, OCH. OCH, OCH, OCH, CH,
• camptothecin (34) and several camptothecin derivatives 33 and 30, as well as nitidine (28), fagaronine (29), the anticancer indenoisoquinolinium species 31 and 32 (structures given in Scheme 5) were used as control agents for experiments examining topoisomerase I-mediated DNA cleavage and/or cell growth inhibition experiments.
• GI50 values i.e., the concentration causing 50%o growth inhibition
• MGM mean graph midpoint
• the MGM is based on a calculation of the average GI50 for all of the cell lines tested (approximately 55) in which GI50 values below and above the test range (10 4 to 10 "8 molar) are taken as the minimum (10 "8 molar) and maximum (10 "4 molar) drug concentrations used in the screening test.
• the relative activities of the compounds in the topoisomerase I cleavage assay are listed in Table 1. In Table 1 , results of the topoisomerase I cleavage assay are listed as follows:
• N-ethylisoquinolinium species 27 (MGM 13 ⁇ M) and the relatively simple indenoisoquinolines 7 (MGM 16 ⁇ M) and 8 (MGM 14 ⁇ M), both lacking substituents on the aromatic rings, were slightly more cytotoxic than 1.
• the isoquinolinium salt 27 was comparable to 1 regarding topoisomerase I cleavage activity, the other more cytotoxic analogs were significantly less potent than 1 in the topoisomerase I cleavage assay.
• camptothecin-induced cleavage complexes have been used to compare the molecular interactions between camptothecin derivatives and topoisomerase I cleavage complexes.
• the cleavage sites induced by camptothecin and the indenoisoquinoline derivatives 1, 13c, 19a, 26, and 27 were reversed by salt treatment. This reversibility is consistent with the reversible trapping of topoisomerase cleavage complexes by the indenoisoquinolines.
• planar indenoisoquinoline system appears to be a necessary, although not sufficient, condition for potent activity in the topoisomerase I cleavage assay.
• the non-planar systems 20-25 were all inactive or displayed weak activity vs. topoisomerase I (Table 1).
• a direct comparison can be made between the planar indenoisoquinoline 1 and the corresponding non-planar, cis dihydro compound 20.
• Compound 1 displays good activity in the topoisomerase I cleavage assay, whereas the activity of 20 is weak.
• indenoisoquinolines 3-6 and 13f-13j are all planar ring systems that are inactive as topoisomerase I inhibitors.
• Table 2 shows the Pearson correlation coefficients derived from the GI 50 values for compound 1 , camptothecin (34) and several camptothecin derivatives 33 and 30, as well as nitidine (28), fagaronine (29), the anticancer indenoisoquinolinium species 31 and 32, and several of the new indenoisoquinoline derivatives.
• the Pearson correlation coefficients quantify the degree of similarity in the cytotoxicity profiles of the compounds listed in the NCI panel of approximately 55 cancer cell lines. The analysis was performed using the COMPARE algorithm, which was developed to facilitate the rapid selection of compounds with similar or novel cytotoxicity profiles relative to established anticancer agents with known mechanisms of action.
• the data pattern of an agent of interest correlates well with the data pattern of a known agent with a known mechanism of action, then the hypothesis is formed that the agent of interest may have the same mechanism of action as that of the known agent.
• the dihydroindenoisoquinoline derivative 20 correlates well with the camptothecins 30, 33, and 34, suggesting that the cytotoxicity of 20 may be due to its topoisomerase I inhibitory activity.
• topoisomerase II Since a number of topoisomerase I poisons also inhibit topoisomerase II, we tested the induction of topoisomerase II cleavage complexes by indenoisoquinolines. Our results show that compound 26 induced topoisomerase II cleavage complexes at sites which often did not overlap with the topoisomerase II sites induced by VP-16 (etoposide). Compound 27 had only marginal topoisomerase II activity at 100 ⁇ M and compounds 13 c, 19a and 1 had no effect on topoisomerase II cleavage activity. Compounds 7 and 8 also exhibited weak topoisomerase II activity and compounds 13b, 13k, 20, 21 and 22 had no effect on topoisomerase II cleavage. These results indicate that the indenoisoquinolines are prominent topoisomerase I inhibitors, except for the two derivatives 26 and 27 that also produce DNA unwinding.
• Example 1 6-Ethyl-5,6-dihydro-5,ll-diketo-llH-indeno[l,2- e]isoquinoIine (3): Ethylamine (0.2 mL, 3 mmol) was added to a stirred solution of benz[c ]indeno[l,2- 7]pyran-5, 11-dione (2) (0.49 g, 2 mmol) in CHC1 3 (10 mL). The bright orange mixture stirred overnight.
• Example 4 5,6-Dihydro-5,l l-diketo-6-(methoxycarbonylmethyl)- HH-indeno[l,2-c]isoquinoline (6): Triethylamine (2.7 mL, 19.4 mmol) was added to a stirred solution of glycine methyl ester hydrochloride (1.57 g, 12.5 mmol) in chloroform (30 mL). After 1 h, benz[J]indeno[l,2- yran-5, 11-dione (2) (1.24 g, 5.0 mmol) was added to the mixture.
• Example 5 5,6-Dihydro-6-(4-hydroxy-l-butyl)-5,ll-diketo-lLH- indeno[l,2- c]isoquinoline (7): 4-Amino-l-butanol (0.891 g, 10 mmol) was added to a chloroform (30 mL) solution of benz[ ]indeno[l,2-6]pyran-5, 11-dione (2) (2.48 g, 10 mmol) and the reaction mixture was stirred at room temperature 2 days. The reaction mixture turned dark red.
• reaction mixture was taken in chloroform (100 mL) and washed with water (2 x 50 mL), 0.5 N HCl (50 mL), brine (100 mL) and dried (Na 2 SO 4 ) and concentrated to give the crude product.
• Example 6 5,6-Dihydroxy-6-(5-hydroxy-l-pentyI)-5,l 1-diketo- HH-indeno[l,2-c]isoquinoIine (8).
• 5-Amino-l-pentanol (1.03 g, 10 mmol) was added to a chloroform (20 mL) solution of benz[ /]indeno[l,2- ⁇ ]pyran-5, 11-dione (2) (2.48 g, 10 mmol) and the reaction mixture was sti ⁇ ed at room temperature overnight. The reaction mixture turned dark red.
• reaction mixture was taken in chloroform (100 mL) and washed with water (2 x 50 mL), 0.5 N HCl (50 mL), brine (100 mL) and dried (Na 2 SO 4 ) and concentrated to give the crude product.
• the TLC showed traces of starting material.
• Example 7 c s-4-Carboxy-3,4-dihydro-N-methyI-3-(3',4'- methylenedioxyphenyl)-l(2H)isoquinolone (12a): ⁇ omophthalic anhydride (10a) (0.81 g, 5 mmol) was added to a stirred solution of 3,4- methylenedioxybenzylidenemethylamine (11a) (0.82 g, 5 mmol) in chloroform (5 mL).
• Example 8 5,6-Dihydro-5,ll-diketo-6-methyl-8,9- methyIenedioxy-HH-indeno[l,2-c]isoquinoline (13a).
• Thionyl chloride 8.1 mL was added with stirring to the cis acid 12a (0.7 g, 2.1 mmol). The yellowish-brown mixture became orange within 15 min and after 30 min was red. After 4 h, the reaction mixture was diluted with benzene (25 mL) and evaporated to dryness.
• Example 9 3,4-MethylenedioxybenzyIidenebutylamine (lib): Piperonal (7.5 g, 50 mmol) and w-butylamine (6 mL, 75 mmol) were stirred in chloroform (100 mL) in the presence of anhydrous MgSO 4 (5 g) at room temperature for 4 h. The mixture was filtered and the residue was washed with chloroform (20 mL).
• Example 10 c s-N-(l-Butyl)-4-carboxy-3,4-dihydro-3-(3',4'- methylenedioxyphenyl)-l(2H)-isoquinolone (12b): ⁇ omophthalic anhydride (10a) (3.24 g, 20 mmol) was added to a chloroform (20 mL) solution of the imine lib (4.1 g, 20 mmol) and the mixture was stirred at room temperature for 45 min, after which the TLC showed the complete disappearance of the starting materials. The reaction mixture was concentrated to remove chloroform completely. The residue was dissolved in hot ethyl acetate (100 mL) and left at room temperature for 12 h.
• Example 11 6-(l -Butyl)-5,6-dihydro-5,ll-diketo-8,9- methylenedioxy-HH-indeno[l,2 -cjisoquinoline (13b): Thionyl chloride (30 mL) was added dropwise to the acid 12b (3.35 g, 0.089 ml) with stirring. The resulting solution was stirred at room temperature for 12 h, after which the solution turned dark pink. Benzene (20 mL) was added to the reaction mixture and it was concentrated under reduced pressure.
• Example 12 3,4-DimethoxybenzyIideneallylamme (lie): Allylamine (6 mL, 80 mmol) was added to a solution of 3,4-dimethoxybenzaldehyde (8.3 g, 50 mmol) in dichloromethane (50 mL) in the presence of anhydrous magnesium sulfate (5 g) and the reaction mixture was stirred at room temperature overnight.
• Example 13 c/s-N-AUyl-4-carboxy-3,4-dihydro-6,7-dimethoxy-3- (3',4'-methyIenedioxy phenyl)-l(2H)isoquinolone (12c).
• Dimethoxyhomophthalic anhydride (10b) (1.11 g, 5 mmol) was added to a chloroform (10 mL) solution of the imine lie (0.945 g, 5 mmol) and the mixture was stirred at room temperature for 45 min, after which the TLC showed the complete disappearance of the starting materials and a white precipitate formed in the reaction mixture.
• Example 14 6-AIlyI-2,3-dimethoxy-5,6-dihydro-5,l 1 -oxo-8,9- (methylenedioxy)-HH-indeno[l,2-c]isoquinoline (13c): Treatment of 12c (2.05 g, 5 mmol) with Eaton's reagent (10% P 2 O 5 , in methanesulfonic acid, 60 mL) at room temperature with stirring in an open flask for 24 h resulted in a mixture of 22 and 13c.
• Eaton's reagent 10% P 2 O 5 , in methanesulfonic acid, 60 mL
• Example 16 6-(l-ButyI)-5,6-dihydro-5,ll-diketo-2,3-dimethoxy- 8,9-methylenedioxyllH-indeno[l,2-c]isoquinoline (13d).
• Thionyl chloride (30 mL) was added dropwise to the acid 12d (2.135 g, 5 mmol) with stirring. The resulting solution was stirred at room temperature for 12 h after which the solution turned dark pink.
• Benzene (20 mL) was added to the reaction mixture and it was concentrated under reduced pressure.
• Example 17 3,4-MethylenedioxybenzyIidenebe ⁇ zylamine (lie). Piperonal (4.5 g, 30 mmol) and benzylamine (3.21 g, 30 mmol) were stirred in methylene chloride (30 mL) in the presence of anhydrous MgSO 4 (5 g) at room temperature for 4 h.
• Example 18 cw-N-Benzyl-4-carboxy-3,4-dihydro-6,7-dimethoxy- 3-(3',4'-methylenedioxyphenyl)-l(2H)isoquinolone (12e): 4,5- Dimethoxyhomophthalic anhydride (10b) (1.11 g, 5 mmol) was added to a chloroform (10 mL) solution of the imine lie (1.19 g, 5 mmol) and the mixture was stirred at room temperature for 2 h, after which the TLC showed the complete disappearance of the starting materials and a white precipitate formed in the reaction mixture.
• Example 19 6-Benzyl-5,6-dihydro-5,ll-diketo 2,3-dimethoxy-8,9- methyIenedioxy-HH-indeno[l,2-c]isoquinoline (13e).
• Thionyl chloride (10 mL) was added dropwise to the acid 12e (1.15 g, 1.5 mmol) with stirring. The resulting mixture was stirred at room temperature for 5 h, after which the solution turned purple.
• Benzene (20 mL) was added to the reaction mixture and it was concentrated under reduced pressure.
• Dimethoxyhomophthalic anhydride (10b) (1.11 g, 5 mmol) was added to a chloroform (10 mL) solution of the imine llf (1.275 g, 5 mmol) and the mixture was stirred at room temperature for 12 h, after which the TLC showed the complete disappearance of the starting materials and a white precipitate formed in the reaction mixture.
• Example 22 6-(p-AnisyI) -2,3-dimethoxy-5,6-dihydro-5,H-diketo- 8,9-methylenedioxy-llH-indeno[l,2-c]isoquinoline (13i).
• Thionyl chloride (9 mL) was added dropwise to the acid 12f (0.822 g, 2 mmol) with stirring. The resulting solution was stirred at room temperature for 5 h, after which the solution turned purple.
• Benzene (20 mL) was added to the reaction mixture and it was concentrated under reduced pressure. The resulting residue was passed through a short column of silica gel (230-400 mesh) eluting with chloroform.
• Example 23 3,4-Dibenzyloxybenzylidenemethylamine (llg). 3,4- Dibenzyloxybenzaldehyde (7.96 g, 25.0 mmol) was added to a 40% aqueous solution of methylamine (10 mL) and the reaction mixture was stirred at room temperature for 3 h.
• Example 24 ⁇ ' s ⁇ - ⁇ ' ⁇ '-Dibeiizylo yphenyr -carboxy-S ⁇ - dihydro-N-methyl-l-2H-isoquino!one (12g).
• ⁇ omophthalic anhydride (10a) (0.81 g, 5 mmol) was added to a stirred solution of 3,4- dibenzyloxybenzylidenemethylamine (llg) (1.66 g, 5 mmol) in chloroform (5 mL).
• Example 25 8,9-Dibenzyloxy-5,6-dihydro-5,l 1 -diketo-6-methyl- HH-indeno[l,2-c]isoquinoIine (13g).
• Thionyl chloride (8.1 mL) was added with stirring to the cis acid 12g (0.7 g, 2.1 mmol). The result was a yellowish-brown mixture that became orange within 15 min and after 30 min was red. After 4 h, the reaction mixture was diluted with benzene (25 mL) and evaporated to dryness. The brownish-red solid was recrystallized from methanol and passed through a short column (SiO 2 ), eluting with chloroform, to give a brown solid (0.
• Example 26 cis-3-(3',4'-Dibenzyloxyphenyl)-4-carboxy-3,4- dihydro-N-methyl-6,7-dimethoxy-l-(2H)-isoquinolone (12h).
• 3,4- Dimethoxyhomophthalic anhydride (10b) (0.56 g, 2.5 mmol) was added to a stirred solution of 3,4-dibenzyloxy benzylidenemethylamine (llg) (0.83 g, 2.5 mmol) in chloroform (3 mL). After 30 min, the yellow mixture became heterogeneous and ether was added to further precipitate the product.
• Example 28 3,4,5-TrimethoxybenzyIidenemethylamine (Hi). 3,4,5-Trimethoxybenzaldehyde (7.81 - 40.0 mmol) and a 40% aqueous solution of methylamine (20 mL) were stirred at room temperature for 2.5 h.
• Example 30 5,6-Dihydro-5,ll-diketo-6-methyl-2,3,8,9,10- pentamethoxy-llH-indeno[l,c]isoquinoline (13i).
• Thionyl chloride (15 mL) was added with stirring to the cis acid 12i (1.2 g 2.8 mmol). The result was a yellow mixture that became dark red within 15 min. After 4 h, the reaction mixture was diluted with benzene (25 mL) and evaporated to dryness.
• Example 31 c «-4-Carboxy-3,4-dihydro-N-methyl-3-(3',4',5'- trimethoxyphenyl)-l(2H)isoquinolone (12j).
• ⁇ omophthalic anhydride (10a) (0.32 g, 2 mmol) was added to a stirred solution of 3,4,5- trimethoxybenzylidenemethylamine (Hi) (0.46 g, 2 mmol) in chloroform (5 mL).
• Example 32 5,6-Dihydro-5,l l-diketo-6-methyl-8,9,l 0-trimethoxy- HH-indeno[l,2-c]isoquinoline (13j).
• Thionyl chloride (10 mL) was added with stirring to 12j (200 mg, 0.5 mmol). After 4 h, the reaction mixture was diluted with benzene (50 mL) and evaporated to dryness.
• Example 33 3,4-Methylenedioxybenzylideneethylamine (Ilk). Piperonal (20.1 g, 0.14 mol) and a 70% aqueous solution of ethylamine (20 mL) were stirred at room temperature for 3 h. The mixture was extracted with ether (4 x 50 mL).
• Example 34 c s-4-Carboxy-N-ethyl-3-(3',4'- methylenedioxyphenyI)-6,7-dimethoxy3,4-dihydro-l(2H)isoquinolone (12k).
• 3,4- Methylenedioxybenzylideneethylamine (Ilk) (0.89 g, 5.0 mmol) was stirred in chloroform (5.0 mL) and 4,5-dimethoxyhomophthalic anhydride (10b) (1.11 g, 5.0 mmol) was added.
• Example 35 6-EthyI-5,6-dihydro-5,ll-diketo-2,3-dimethoxy-8,9- methylenedioxy-llH-indeno[l,2-c] isoquinoline (13k).
• Thionyl chloride (6.0 mL) was added with stirring to the cis acid 12k (0.58 g, 1.5 mmol) and the reaction mixture became dark reddish-purple and heterogeneous. After 4 h, the reaction mixture was diluted with benzene (5.0 mL) and evaporated to dryness.
• Example 36 General Procedure for the Synthesis of Imines 17.
• the O-TBDMS protected aminols 15 were synthesized using a reported procedure.
• the imines 17 were synthesized by treating the O-TBDMS protected aminols (9 mmol) with piperonal (9 mmol) in chloroform (20 mL) in the presence of anhydrous magnesium sulfate (2 g) at room temperature for 3 h. The imines were used as such for the next reaction without further purification. The crude yield of the imines 17 were quantitative.
• Example 37 General Procedure for the Synthesis of Isoquinolones 18. 4,5-Dimethoxyhomophthalic anhydride (10b) (2.22 g, 10 mmol) was added to a chloroform (20 mL) solution of the imine 17a of 17b (10 mmol) and the mixture was stirred at room temperature for 12 h, after which the TLC showed the complete disappearance of the starting materials and a white precipitate formed in the reaction mixture. The precipitated product was filtered off and washed with chloroform (5 mL) and dried to give pure 18a or 18b.
• Example 38 ⁇ s-N-(t-Butyldimethylsilyloxybut-l-yl)-4-carboxy- 3,4-dihydro-6,7dimethoxy-3-(3 , ,4'-methylenedioxyphenyl)-l(2H)isoquinolone (18a).
• Example 40 General Procedure for the Synthesis of Indenoisoquinolines 19.
• Thionyl chloride (10 mL) was added dropwise to the acid 18 (2 mmol) with stirring. The resulting solution was stirred at room temperature for 5 h after which the solution turned purple.
• Benzene (20 mL) was added to the reaction mixture and it was concentrated under reduced pressure. The resulting residue was passed through a short column of silica gel (230 - 400 mesh) eluting with chloroform:methanol (95:5). Concentration of the eluent resulted in a pink solid which was crystallized from ethyl acetate to obtain pure indenoisoquinolines 19.
• Example 42 5,6-Dihydro-6-(4-h,vdroxypent-l-yl)-5,l l-diketo-2,3- dimethoxy-8,9-methylenedioxy-llH-indenoisoquinoline (19b).
• the indenoisoquinoline 18b was isolated in 79% yield: mp 288-290°C; IR (KBr) 3411, 2929, 1698, 1653, 1582, 1550 cm “1 ; 'H NMR (DMSO-d 6 , 80°C) ⁇ 7.91 (s, 1 H), 7.53 (s, 1 H), 7.21 (s, 1 H), 7.07 (s, 1 H), 6.18 (s, 1 H), 4.41 (bs, 2 H), 3.90 (s, 3 H), 3.86 (s, 3 H), 3.60 (bs, 1 H), 3.40 (bs, 2 H), 1.88 - 1.70 (m, 2 H), 1.60 - 1.40 (m, 4 H); CIMS m/z (relative intensity) 438 (MH + , 100).
• Example 44 c s-6-Ethyl-5,6,l 2,13-tetrahydro-2,3-dimethoxy-5,l 1 - dioxo-8,9-(methylene-dioxy)- ⁇ -indeno[l,2-c]isoquinoline (21).
• the acid 12k (3.99 g, 3 mmol) was added slowly under nitrogen to a solution of degassed Eaton's reagent (10%, P 2 0 5 in methanesulfonic acid, 120 mL) with stirring over a period of 20 min.
• the reaction mixture was stirred at room temperature for 4 h, after which the mixture was added dropwise to water (600 mL) with stirring.
• Example 45 c s-6-Allyi-5,6,12,13-tetrahydro-2,3-dimethoxy-5,ll- dioxo-8,9-(methylenedioxy)-(HH)indeno[l,2-c]isoquinoline (22).
• Indenoisoquinoline 22 was synthesized in 72% yield from the acid 12c in a similar procedure for the synthesis of indenoisoquinoline 21.
• Example 46 5,6-Dihydro-5,l 1 -diketo-2,3,8-trimethoxy-6-methyl- 9[(methyIsulfonyl)oxy]-(llH)indeno[l,2-c]isoquinoline (23). This compound was prepared as described previously in J. Med. Chem. 1985, 28, 1031-1036.
• Example 47 6-EthyI-5,6,12 ⁇ ,13 ⁇ -tetrahydro-ll ⁇ -hydroxy-2,3- dimethoxy-8,9-(methylenedioxy)-5-oxo- llH-indeno[l,2-c]isoquinoIine (24).
• the indenoisoquinoline 21 (0.381 g, 1 mmol) was heated at reflux with a 1 M solution of borane-tetrahydrofuran complex (4 mL) in dry T ⁇ F (30 mL) for 1 h. After cooling, the reaction mixture was concentrated and the residue was dissolved in EtOAc (60 mL) and glacial acetic acid was added dropwise until p ⁇ 5.
• Example 49 6-(3-Carboxy-I-propyl)-5,6-dihydro-5,l 1 -diketo-11/7- indeno[l,2-c]isoquinoline (26).
• the indenoisoquinoline 7 (0.319 g, 1 mmol) was dissolved in acetone (50 mL) and cooled in an ice bath. Jones reagent was added dropwise to the cold solution of the alcohol until the red color of the reagent persisted. The excess Jones reagent was quenched by adding few drops of isopropyl alcohol. The reaction mixture was filtered through a small pad of celite and the residue was washed with acetone (50 mL).
• Example 50 6-Ethyl-2,3-dimethoxy-8,9-(methylenedioxy)-l 1/7- indeno[l,2-c]isoquinolinium Chloride (27).
• the amino alcohol 25 (0.738 g, 2 mmol) was heated at reflux with 5% palladium on charcoal (0.265 g) in glacial acetic acid (100 mL) for 20 h. After cooling, the mixture was filtered through a small pad of celite, and the solvent was evaporated to give a brown residue. The residue was dissolved in water (50 mL) and ethanol (6 mL) to give a light brown solution, to which was added 15% aqueous sodium chloride (10 mL).
• the 161 bp fragment from pBluescript SK(-) phagemid DNA (Stratagene, La Jolla, CA) was cleaved with the restriction endonuclease Pvu II and Hind III (New England Biolabs, Beverly, MA) in supplied NE buffer 2 (10 ⁇ L reactions) for 1 h at 37 °C, separated by electrophoresis in a 1% agarose gel made in IX TBE buffer.
• the 161 bp fragment was eluted from the gel slice (centrilutor by Amicon) and concentrated in a centricon 50 centrifugal concentrator (Amicon, Beverly, MA).
• Example 52 Topoisomerase II-Mediated DNA Cleavage Assays Using 5'-End-labeled Human C-myc DNA.
• a 403-base pair DNA fragment of the human c-myc gene from the junction between the first intron and the first exon was prepared by PCR between positions 2671 and 3073 using the oligonucleotides 5'-TGCCGCATCCACGAAACTTTGC-3' as sense primer and 5'- GAACTGTTCAGTGTTTACCCCG-3' as antisense primer. Single-end labeling of these DNA fragments was obtained by 5 '-end labeling of the adequate primer oligonucleotide.
• the 5 '-end-labeled DNA fragments were equilibrated with or without a drug in 1%> dimethyl sulfoxide, 10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5 mM MgCl 2 , 2 mM dithiothreitol, 0.1 mM Na 2 EDTA, 1 mM ATP, and 15 ⁇ g/mL bovine serum albumine for 5 min before addition of purified human topoisomerase II (40-70 ng) in a 10 ⁇ L final reaction volume.
• the reactions were performed at 37 °C for 30 min and thereafter stopped by adding 1%> sodium dodecyl sulfate (SDS) and 0.4 mg/mL proteinase K (final concentrations) followed by an additional incubation at 50 °C for 30 min. Samples were ethanol-precipitated before separation of the topoisomerase Il-cleaved fragments on denaturing polyacrylamide gels.
• the sequencing gels were made of 7%> polyacrylamide in IX TBE buffer (90 mM Tris borate, 2 mM EDTA, pH 8.3 ).
• Electrophoresis was performed at 2500 V (60 W) for 2-5 h. The gels were dried and visualized using a Phosphoimager and ImageQuant software.
• Example 53 SV40 DNA Unwinding Assay. Reaction mixtures (10 ⁇ L final volume) contained 0.3 ⁇ g supercoiled SV40 DNA in reaction buffer (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5 mM MgCl 2 , 0.1 mM EDTA, 15 ⁇ /mL bovine serum albumin) and 10 units of purified calf thymus topoisomerase I. Reactions were performed at 37°C for 30 min and terminated by the addition of 0.5% SDS, and then 1.1 ⁇ L of 10X loading buffer (20% Ficol 400, 0.1 M Na 2 EDTA pH 8, 1.0% SDS.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Other In-Based Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22299324

Family Applications (1)

Country Status (8)

Cited By (28)

Families Citing this family (7)

Citations (1)

Family Cites Families (4)

• 1999
  • 1999-10-14 CA CA2347100A patent/CA2347100C/en not_active Expired - Fee Related
  • 1999-10-14 AT AT99970323T patent/ATE424204T1/de not_active IP Right Cessation
  • 1999-10-14 WO PCT/US1999/023900 patent/WO2000021537A1/en not_active Ceased
  • 1999-10-14 DE DE69940523T patent/DE69940523D1/de not_active Expired - Lifetime
  • 1999-10-14 AU AU12043/00A patent/AU765135B2/en not_active Ceased
  • 1999-10-14 EP EP99970323A patent/EP1123099B1/en not_active Expired - Lifetime
  • 1999-10-14 US US09/807,340 patent/US6509344B1/en not_active Expired - Lifetime
  • 1999-10-14 EP EP09000858A patent/EP2050452A1/en not_active Withdrawn
  • 1999-10-14 JP JP2000575513A patent/JP4580556B2/ja not_active Expired - Fee Related

Patent Citations (1)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events